Top 3 Penny Stocks To Watch In October 2026

AI related shares have just gone through a harsh global selloff after hotter than expected US inflation, reminding traders that expensive stories can crack quickly when borrowing costs rise. That kind of shakeout often pushes attention toward smaller companies with sturdier finances. This article looks at a group of low priced stocks with stronger balance sheets and limited dilution, and highlights 3 that fit this resilient penny stock theme.

The three companies covered below are just a starting sample from this resilient penny stock theme. The wider screen surfaced 8 more low priced businesses with similar balance sheets, ownership structures and recent share strength that are not outlined here.

If you want to go straight to the source and identify, analyze and rank the highest conviction ideas from this elite penny stock universe, head into the Elite Penny Stocks screener.

Nuvation Bio (NUVB)

Nuvation Bio is a clinical-stage oncology specialist that fits the Elite Penny Stocks theme through its targeted cancer therapies and relatively disciplined capital use, with IBTROZI and safusidenib forming the commercial and late stage pillars investors focus on today.

Nuvation Bio generates about US$169.9 million from oncology development activities, supported by US$124 million from the United States, US$30 million from Japan and US$16 million from China, and carries a market value of roughly US$1.66b.

For this screener, Nuvation Bio matters because it is not simply a low priced ticker chasing hype. It anchors the growth story in targeted medicines that could reshape treatment outcomes for tightly defined cancer populations.

"IBTROZI is rapidly emerging as the preferred therapy in ROS1 positive non small cell lung cancer, with best in class durability, strong brain penetration and growing first line use."

What ultimately happens to investor returns here depends on how one underappreciated pressure shapes future pricing power and long term treatment demand.

That pressure point is exactly what the full narrative for Nuvation Bio unpacks in detail, separating short term noise from what could be quietly accelerating long run oncology value.

PagSeguro Digital (PAGS)

PagSeguro Digital leans into the Elite Penny Stocks theme through PagBank, where card machines, PIX payments and app based banking give small Brazilian merchants a simple way to accept money, move cash and tap credit in a single ecosystem.

PagSeguro generates about R$19.8 billion from financial service agents and has a market value near US$3.0 billion, tying its Elite Penny Stocks screener role to a payments led financial platform rather than a narrow monoline bank.

"The single biggest lever is the credit portfolio. It sits at roughly R$5 billion today and management targets R$25 billion by 2029, which is a fivefold expansion."

What happens to PagSeguro’s earnings and funding costs if one quiet shift in how this credit engine is financed moves against current expectations?

That funding mix is exactly where the story starts to bend, and the full narrative for PagSeguro Digital shows how credit growth, risk and PagSeguro’s valuation could be quietly decoupling.

CBAK Energy Technology (CBAT)

CBAK Energy Technology is a China based battery manufacturer focused on lithium ion and sodium ion cells and complete systems for electric vehicles and stationary storage, generating about US$123 million from CBAK and US$107 million from Hitrans segments, with a market cap near US$108 million.

CBAK Energy Technology taps directly into the Elite Penny Stocks theme through its battery cells and packs that serve EV and energy storage markets. This gives investors exposure to hardware that already ships into mobility fleets and power systems.

"Completion and utilization ramp of the new 32140 and 40135 production lines in Nanjing and Dalian, where demand already exceeds current output, could translate existing order visibility into higher revenue and improved gross margins as unit costs normalize."

The appeal of CBAK Energy Technology in this screener now depends on how one unseen cost pressure affects those future margins.

If that cost pressure is the real swing factor, the full narrative for CBAK Energy Technology shows where CBAK Energy Technology’s margin story could be accelerating or quietly stalling.

Seeking Fresh Alternatives Before They Fly

Markets move fast and the sweetest breakouts rarely wait. Scan fresh ideas with real momentum while they are still under the radar for now. Get in early.

• Spot cash generative opportunities before they get crowded by screening a curated set of 32 high quality undervalued stocks that pair earnings strength with disciplined balance sheets.
• Track capital returning candidates that aim to keep payouts flowing by scanning a hand picked pool of 7 dividend fortresses with defensible cash coverage.
• Follow the real economy of materials and infrastructure by reviewing a focused basket of 16 top copper producer stocks tied to long term electrification themes.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com